Skip to Content
Search Menu

Exceptional Response of Lorlatinib and Cabozantinib Combination in ROS1-Rearranged NSCLC

In this MEDtalk, Assistant Professor Tejas Patil presents a case with one of his patients having an exceptional response to lorlatinib and cabozantinib in ROS1-rearranged NSCLC with acquired F2004V and L2086F resistance.
Tejas Patil

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Relateret indhold

CheckMate 227: 6-year data on the treatment of locally advanced NSCLC with Opdivo and Yervoy  

/ BestPractice Nordic
Lung cancerNSCLCWCLC23

Adjuvant treatment with 3rd generation EGFR-TKI can increase progression-free survival 

/ BestPractice Nordic
Lung cancerNSCLCWCLC23

WCLC 2023 – NSCLC: New Data on Perioperative Immunotherapy Treatment 

/ BestPractice Nordic
ImmunotherapyLung cancerNSCLCWCLC23
Timothy F. Burns

Osimertinib for the Treatment of EGFR-Mutant NSCLC in the Adjuvant Setting

/ Timothy F. Burns
NSCLC Play the Video 10:15
Birgitte Bjørnhart

Real-World Studies Highlight NSCLC Data Gaps and Survival Differences from Randomized Controlled Trials

/ Birgitte Bjørnhart
DSKO23Lung cancerNSCLC Play the Video 5:04
Astrid Telhaug Karlsson

Survival Rates for Patients with NSCLC with Brain Metastases following Whole Brain Radiotherapy

/ Astrid Telhaug Karlsson
ELCC23Lung cancerNSCLC Play the Video 3:22
Niels Reinmuth

Current Aspects in Early-Stage NSCLC – Perspectives from ELCC23

/ Niels Reinmuth
ELCC23Lung cancerNSCLC Play the Video 3:54
Siow Ming Lee

First-line atezolizumab treatment significantly improves overall survival in patients with NSCLC and not eligible for a platinum-containing regimen

/ Siow Ming Lee
ESMO22Lung cancerNSCLC Play the Video 5:14
Roy S. Herbst

New combination with durvalumab improved ORR and PFS for unresectable Stage III NSCLC

/ Roy S. Herbst
ESMO21NSCLC Play the Video 4:03
Back to top